Management Strategies in Septic Coagulopathy: A Review of the Current Literature
- PMID: 36673595
- PMCID: PMC9858837
- DOI: 10.3390/healthcare11020227
Management Strategies in Septic Coagulopathy: A Review of the Current Literature
Abstract
One of the 'organs' that can be affected by sepsis is the coagulation system. Coagulopathy in sepsis may take the form of sepsis-induced coagulopathy (SIC) or sepsis-associated disseminated intravascular coagulation (DIC). It is important to identify SIC early, as at this stage of coagulopathy anticoagulants may be of the greatest benefit. The most recent diagnostic scoring systems for septic coagulopathy come from the International Society on Thrombosis and Hemostasis and the Japanese Association for Acute Medicine. Recommendations regarding the management of septic coagulopathy differ between organizations. Moreover, septic coagulopathy is an area of intense research in recent years. Therefore we searched three databases to review the most recent management strategies in septic coagulopathy. The mainstream management strategies in septic coagulopathy include the causal treatment of sepsis, unfractionated heparin, low-molecular-weight heparin, antithrombin, and recombinant human thrombomodulin. The last two have been associated with the highest survival benefit. Nevertheless, the indiscriminate use of these anticoagulants should be avoided due to the lack of mortality benefit and increased risk of bleeding. The early diagnosis of SIC and monitoring of coagulation status during sepsis is crucial for the timely management and selection of the most suitable treatment at a time. New directions in septic coagulopathy include new diagnostic biomarkers, dynamic diagnostic models, genetic markers for SIC management, and new therapeutic agents. These new research avenues may potentially result in timelier SIC diagnosis and improved management of all stages of septic coagulopathy by making it more effective, safe, and personalized.
Keywords: antithrombin; coagulopathy; disseminated intravascular coagulation; heparin; management; sepsis; thrombomodulin; treatment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Taylor F.B., Toh C.H., Hoots W.K., Wada H., Levi M., Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 2001;86:1327–1330. doi: 10.1055/s-0037-1616068. - DOI - PubMed
-
- Schmitt F.C.F., Manolov V., Morgenstern J., Fleming T., Heitmeier S., Uhle F., Al-Saeedi M., Hackert T., Bruckner T., Schöchl H., et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: Results of an observational pilot study. Ann. Intensive Care. 2019;9:19. doi: 10.1186/s13613-019-0499-6. - DOI - PMC - PubMed
-
- Gando S., Iba T., Eguchi Y., Ohtomo Y., Okamoto K., Koseki K., Mayumi T., Murata A., Ikeda T., Ishikura H., et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria. Crit. Care Med. 2006;34:625–631. doi: 10.1097/01.CCM.0000202209.42491.38. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
